Ionis Pharmaceuticals Files 8-K on Financials
Ticker: IONS · Form: 8-K · Filed: Oct 29, 2025 · CIK: 874015
Sentiment: neutral
Topics: financial-reporting, 8-K
TL;DR
IONIS filed an 8-K on Oct 29, 2025, updating financials. Check it out.
AI Summary
Ionis Pharmaceuticals, Inc. filed an 8-K on October 29, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 2855 Gazelle Court, Carlsbad, CA 92010. Ionis Pharmaceuticals, previously known as ISIS Pharmaceuticals Inc., is incorporated in Delaware.
Why It Matters
This 8-K filing provides an update on Ionis Pharmaceuticals' financial performance and condition, which is crucial information for investors and stakeholders to assess the company's current health and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting financial information and does not appear to contain any significant new risks or material adverse events.
Key Players & Entities
- IONIS PHARMACEUTICALS INC (company) — Registrant
- October 29, 2025 (date) — Report date
- 2855 Gazelle Court, Carlsbad, CA 92010 (location) — Principal Executive Offices
- ISIS PHARMACEUTICALS INC (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing by Ionis Pharmaceuticals?
The primary purpose of this 8-K filing is to report on Ionis Pharmaceuticals' results of operations and financial condition, including financial statements and exhibits.
When was this 8-K report filed?
This 8-K report was filed on October 29, 2025.
Where are Ionis Pharmaceuticals' principal executive offices located?
Ionis Pharmaceuticals' principal executive offices are located at 2855 Gazelle Court, Carlsbad, CA 92010.
What was Ionis Pharmaceuticals' former company name?
Ionis Pharmaceuticals' former company name was ISIS PHARMACEUTICALS INC.
Under which section of the Securities Exchange Act is this report filed?
This report is filed as a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 609 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2025-10-29 07:06:01
Filing Documents
- ef20057869_8k.htm (8-K) — 28KB
- ef20057869_ex99-1.htm (EX-99.1) — 488KB
- image0.jpg (GRAPHIC) — 24KB
- 0001140361-25-039650.txt ( ) — 701KB
- ions-20251029.xsd (EX-101.SCH) — 4KB
- ions-20251029_lab.xml (EX-101.LAB) — 21KB
- ions-20251029_pre.xml (EX-101.PRE) — 16KB
- ef20057869_8k_htm.xml (XML) — 4KB
02
Item 2.02 Results of Operations and Financial Condition. On October 29, 2025, Ionis Pharmaceuticals, Inc. (the " Company ") issued a press release announcing the Company's financial results for the quarter ended September 30, 2025. In addition to disclosing results that are determined in accordance with Generally Accepted Accounting Principles (" GAAP "), the Company also discloses pro forma or non-GAAP results of operations, which are adjusted from GAAP to exclude non-cash compensation expense related to equity awards and the related tax effects. The Company is presenting pro forma information excluding non-cash compensation expense and the related tax effects because the Company believes it better enables financial statement users to assess and compare its historical performance and project its future operating results and cash flows. A copy of the release is furnished with this report as an exhibit pursuant to "Item 2.02. Results of Operations and Financial Condition" of Form 8-K in accordance with SEC Release Nos. 33-8216 and 34-47583. The information in this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the " Exchange Act ") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated October 29, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Ionis Pharmaceuticals, Inc. Dated: October 29, 2025 By: /s/ Patrick R. O'Neil Patrick R. O'Neil Executive Vice President, Chief Legal Officer and General Counsel